Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade

Abstract Immune checkpoint inhibitors have demonstrated broad single-agent antitumor activity and a favorable safety profile that render them attractive agents to combine with other systemic anticancer therapies. Pancreatic cancer has been fairly resistant to monotherapy blockade of programmed cell...

Full description

Bibliographic Details
Main Authors: Jun Gong, Andrew Hendifar, Richard Tuli, Jeremy Chuang, May Cho, Vincent Chung, Daneng Li, Ravi Salgia
Format: Article
Language:English
Published: Wiley 2018-10-01
Series:Clinical and Translational Medicine
Subjects:
Pancreatic cancer
Checkpoint inhibitor
Combination therapy
Immuno-oncology
Clinical trials
Online Access:http://link.springer.com/article/10.1186/s40169-018-0210-9

Internet

http://link.springer.com/article/10.1186/s40169-018-0210-9

Similar Items